Starling Registry Study

CompletedOBSERVATIONAL
Enrollment

1,207

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

February 21, 2024

Study Completion Date

February 21, 2024

Conditions
Hemodynamic Monitoring
Interventions
DEVICE

Starling

Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance that measures the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood. Baxter Healthcare's Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode. Four electrodes are placed at specific areas of the thorax, the impedance to the current flow calculated, and the electrical bioreactance waveform constructed. This information is used to determine cardiac output, and measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling device.

Trial Locations (9)

43210

Baxter Investigational Site, Columbus

62301

Baxter Investigational Site, Quincy

63110

Baxter Investigational Site, St Louis

63141

Mercy Hospital St. Louis, St Louis

66160

Baxter Investigational Site, Kansas City

77555

Baxter Investigational SIte, Galveston

80204

Baxter Investigational Site, Denver

08103

Baxter Investigational Site, Camden

44195-0001

Baxter Investigational Site, Cleveland

All Listed Sponsors
lead

Baxter Healthcare Corporation

INDUSTRY

NCT04648293 - Starling Registry Study | Biotech Hunter | Biotech Hunter